Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis
Identifieur interne : 000069 ( PascalFrancis/Corpus ); précédent : 000068; suivant : 000070Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis
Auteurs : M. Baltzan ; S. Mehta ; T. H. Kirkham ; M. G. CosioSource :
- American journal of respiratory and critical care medicine [ 1073-449X ] ; 1999.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, ≥ 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV1, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 99-0413904 INIST |
|---|---|
| ET : | Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis |
| AU : | BALTZAN (M.); MEHTA (S.); KIRKHAM (T. H.); COSIO (M. G.) |
| AF : | Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University/Montreal, Quebec/Canada |
| DT : | Publication en série; Niveau analytique |
| SO : | American journal of respiratory and critical care medicine; ISSN 1073-449X; Etats-Unis; Da. 1999; Vol. 160; No. 1; Pp. 192-197; Bibl. 35 ref. |
| LA : | Anglais |
| EA : | Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, ≥ 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV1, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis. |
| CC : | 002B07 |
| FD : | Sarcoïdose; Poumon; Stade avancé; Chloroquine; Chimiothérapie; Traitement; Prolongé; Homme |
| FG : | Maladie système; Appareil respiratoire pathologie; Poumon pathologie |
| ED : | Sarcoidosis; Lung; Advanced stage; Chloroquine; Chemotherapy; Treatment; Prolonged; Human |
| EG : | Systemic disease; Respiratory disease; Lung disease |
| SD : | Sarcoidosis; Pulmón; Estadio avanzado; Cloroquina; Quimioterapia; Tratamiento; Prolongado; Hombre |
| LO : | INIST-2013.354000085841210280 |
| ID : | 99-0413904 |
Links to Exploration step
Pascal:99-0413904Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis</title><author><name sortKey="Baltzan, M" sort="Baltzan, M" uniqKey="Baltzan M" first="M." last="Baltzan">M. Baltzan</name><affiliation><inist:fA14 i1="01"><s1>Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University</s1><s2>Montreal, Quebec</s2><s3>CAN</s3></inist:fA14></affiliation></author><author><name sortKey="Mehta, S" sort="Mehta, S" uniqKey="Mehta S" first="S." last="Mehta">S. Mehta</name></author><author><name sortKey="Kirkham, T H" sort="Kirkham, T H" uniqKey="Kirkham T" first="T. H." last="Kirkham">T. H. Kirkham</name></author><author><name sortKey="Cosio, M G" sort="Cosio, M G" uniqKey="Cosio M" first="M. G." last="Cosio">M. G. Cosio</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0413904</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 99-0413904 INIST</idno><idno type="RBID">Pascal:99-0413904</idno><idno type="wicri:Area/PascalFrancis/Corpus">000069</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis</title><author><name sortKey="Baltzan, M" sort="Baltzan, M" uniqKey="Baltzan M" first="M." last="Baltzan">M. Baltzan</name><affiliation><inist:fA14 i1="01"><s1>Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University</s1><s2>Montreal, Quebec</s2><s3>CAN</s3></inist:fA14></affiliation></author><author><name sortKey="Mehta, S" sort="Mehta, S" uniqKey="Mehta S" first="S." last="Mehta">S. Mehta</name></author><author><name sortKey="Kirkham, T H" sort="Kirkham, T H" uniqKey="Kirkham T" first="T. H." last="Kirkham">T. H. Kirkham</name></author><author><name sortKey="Cosio, M G" sort="Cosio, M G" uniqKey="Cosio M" first="M. G." last="Cosio">M. G. Cosio</name></author></analytic><series><title level="j" type="main">American journal of respiratory and critical care medicine</title><title level="j" type="abbreviated">Am. j. respir. crit. care med.</title><idno type="ISSN">1073-449X</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">American journal of respiratory and critical care medicine</title><title level="j" type="abbreviated">Am. j. respir. crit. care med.</title><idno type="ISSN">1073-449X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Chemotherapy</term><term>Chloroquine</term><term>Human</term><term>Lung</term><term>Prolonged</term><term>Sarcoidosis</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Sarcoïdose</term><term>Poumon</term><term>Stade avancé</term><term>Chloroquine</term><term>Chimiothérapie</term><term>Traitement</term><term>Prolongé</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, ≥ 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV<sub>1</sub>, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1073-449X</s0></fA01><fA03 i2="1"><s0>Am. j. respir. crit. care med.</s0></fA03><fA05><s2>160</s2></fA05><fA06><s2>1</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis</s1></fA08><fA11 i1="01" i2="1"><s1>BALTZAN (M.)</s1></fA11><fA11 i1="02" i2="1"><s1>MEHTA (S.)</s1></fA11><fA11 i1="03" i2="1"><s1>KIRKHAM (T. H.)</s1></fA11><fA11 i1="04" i2="1"><s1>COSIO (M. G.)</s1></fA11><fA14 i1="01"><s1>Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University</s1><s2>Montreal, Quebec</s2><s3>CAN</s3></fA14><fA20><s1>192-197</s1></fA20><fA21><s1>1999</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2013</s2><s5>354000085841210280</s5></fA43><fA44><s0>0000</s0><s1>© 1999 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>35 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>99-0413904</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>American journal of respiratory and critical care medicine</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, ≥ 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV<sub>1</sub>, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.</s0></fC01><fC02 i1="01" i2="X"><s0>002B07</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Sarcoïdose</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Sarcoidosis</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sarcoidosis</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Poumon</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Lung</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Pulmón</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Stade avancé</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Advanced stage</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estadio avanzado</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Chloroquine</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Chloroquine</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Cloroquina</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Prolongé</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Prolonged</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Prolongado</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Maladie système</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Systemic disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Enfermedad sistémica</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Lung disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>39</s5></fC07><fN21><s1>263</s1></fN21></pA></standard><server><NO>PASCAL 99-0413904 INIST</NO><ET>Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis</ET><AU>BALTZAN (M.); MEHTA (S.); KIRKHAM (T. H.); COSIO (M. G.)</AU><AF>Respiratory Division and the Division of Neuro-Ophthalmology, Royal Victoria Hospital, McGill University/Montreal, Quebec/Canada</AF><DT>Publication en série; Niveau analytique</DT><SO>American journal of respiratory and critical care medicine; ISSN 1073-449X; Etats-Unis; Da. 1999; Vol. 160; No. 1; Pp. 192-197; Bibl. 35 ref.</SO><LA>Anglais</LA><EA>Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, ≥ 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV<sub>1</sub>, 51.4 ± 28.2 ml/yr [Maintenance] versus 196.3 ± 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 ± 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 ± 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.</EA><CC>002B07</CC><FD>Sarcoïdose; Poumon; Stade avancé; Chloroquine; Chimiothérapie; Traitement; Prolongé; Homme</FD><FG>Maladie système; Appareil respiratoire pathologie; Poumon pathologie</FG><ED>Sarcoidosis; Lung; Advanced stage; Chloroquine; Chemotherapy; Treatment; Prolonged; Human</ED><EG>Systemic disease; Respiratory disease; Lung disease</EG><SD>Sarcoidosis; Pulmón; Estadio avanzado; Cloroquina; Quimioterapia; Tratamiento; Prolongado; Hombre</SD><LO>INIST-2013.354000085841210280</LO><ID>99-0413904</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000069 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:99-0413904
|texte= Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis
}}
| This area was generated with Dilib version V0.6.33. |  |